Xinnate is a pharmaceutical development company in Lund, Sweden developing novel, pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbials and the complex interplay of inflammatory responses. Xinnate runs an ambitious research and clinical program for TCP25 including a clinical study in phase 1b in patients with Epidermolysis bullosa (EB). Late-stage clinical development and commercialization will take place in partnership with one or more leading pharmaceutical companies.
| Website | http://www.xinnate.com |
| Employees | 7 (3 on RocketReach) |
| Founded | 2019 |
| Phone | +46 72 512 03 12 |
| Technologies |
JavaScript
,
HTML
,
PHP
+9 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Biotechnology, Drug Discovery |
| Keywords | Pharmaceutical Development, Drug Development, Biotechnology, Drug Discovery, Biopharma, Novel Therapies, Immunology, Therapeutics, Peptides, Pharmaceutical Peptides, Innovative Medicines, Clinical Development, Immune System, Microbiome Modulation, Preclinical Development, Therapeutic Peptides, Microbial Control, Wound Healing |
| Competitors | Zoetis, Virbac, Boehringer Ingelheim, Elanco, Merck Animal Health, Cegelec Centre Est S.A., Sandvik, BASF, Corteva Agriscience, Merial S.A.S. +33 more (view full list) |
Looking for a particular Xinnate employee's phone or email?
Xinnate Questions
Helene Hartman is the CEO Transient Pharma AB of Xinnate.
3 people are employed at Xinnate.
Top Xinnate Employees
-
Helene Hartman
CEO Transient Pharma AB at Xinnate
Kalmar County, Sweden2 -
2
Related Companies
